-
LDN-193189 for BMP Signaling Workflows
2026-08-15
Learn how to deploy LDN-193189 as an ALK inhibitor in phospho-Smad assays, epithelial barrier models, and multipathway cell-culture systems. This workflow-focused guide connects receptor pharmacology with the six-component corneal epithelial culture paradigm while emphasizing solubility, timing, controls, and interpretation limits.
-
Dual-Action Inhibitors Promote p38α Dephosphorylation
2026-08-14
This preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also accelerate WIP1-mediated removal of the activation-loop phosphate. Structural and biochemical data indicate that inhibitor-stabilized kinase conformations expose the phospho-threonine, suggesting a route to more effective and selective kinase-directed pharmacology.
-
Galectin-1, FIP200, and Hepatic Steatosis
2026-08-14
The 2026 reference study identifies a Galectin-1–FIP200 interaction as a mechanistic link between hepatic steatosis, autophagy impairment, and insulin resistance. Its combination of in vivo gain-of-function modeling, proteomic analysis, interaction mapping, and mutation-based validation provides a framework for testing whether altered cellular glucose handling is a downstream functional consequence.
-
NF 449 for Selective P2X1 Platelet Studies
2026-08-13
NF 449 is a high-potency purinergic receptor antagonist for separating P2X1-driven calcium entry and platelet activation from broader P2-receptor signaling. This practical guide translates published findings into assay setup, concentration selection, controls, troubleshooting, and antithrombotic agent research workflows.
-
NF 449: Decoding P2X1 in Platelet Assays
2026-08-13
NF 449 is a potent purinergic receptor antagonist that reveals how P2X1 signaling contributes to platelet activation and thrombosis. This guide focuses on translating receptor potency into better assay design, endpoint selection, and interpretation for platelet and antithrombotic research.
-
EDTA-Free Protease Inhibitor Cocktail for OXPHOS
2026-08-12
The Protease Inhibitor Cocktail is an EDTA-Free Protease Inhibitor solution for preserving proteins during cell and tissue extraction. Its multi-component formulation targets several protease classes, supporting reproducible Western blotting, co-immunoprecipitation, pull-down, imaging, and kinase workflows.
-
IGF2BP3, FZD1/7, and Carboplatin Resistance in TNBC
2026-08-12
This 2025 Cancer Letters study identifies an IGF2BP3–FZD1/7 regulatory axis that maintains stem-like properties and promotes Carboplatin resistance in triple-negative breast cancer. By combining transcriptomic analysis, cancer stem cell validation, RNA-binding studies, and pharmacological inhibition, the authors provide a mechanistic rationale for targeting FZD1/7 to resensitize TNBC stem-like cells to platinum chemotherapy.
-
Arachidonic Acid and Rapid Vaccine Immunity
2026-08-11
The reference study shows that dietary arachidonic acid accelerates rabies vaccine-induced neutralizing antibody responses in mice and human volunteers. Its mechanistic analysis links lymph-node arachidonate metabolism, prostaglandin I2 signaling, CD86 expression, and B-cell activation-induced cytidine deaminase to stronger humoral immunity.
-
Isoprenaline Hydrochloride: Designing Better Assays
2026-08-10
Isoprenaline Hydrochloride, also known as isoproterenol, is more than a generic β-adrenergic stimulus. This guide shows how to design mechanistically informative cardiac, vascular, and heart–brain assays by aligning exposure, physiological readouts, and causal controls.
-
Self-Amplifying RNA Vaccines Improve Influenza Protection
2026-08-09
The reference study shows that self-amplifying RNA can overcome the weak influenza B responses observed with conventional mRNA vaccination in mice. At a low RNA dose, the saRNA formulation generated durable antibody responses and complete protection against influenza B challenge, highlighting a dose-sparing strategy for subtype-diverse influenza vaccines.
-
Merbromin as a Mixed-Type SARS-CoV-2 3CLpro Inhibitor
2026-08-08
A 2022 study identified merbromin as a selective inhibitor of the SARS-CoV-2 main protease, 3CLpro, through screening of approximately 6,000 compounds. Enzyme kinetics, binding assays, and molecular docking indicated mixed-type inhibition involving two potential binding sites, while comparison with Proteinase K, trypsin, and papain supported protease selectivity under the reported assay conditions.
-
Ions Improve CPP-Mediated Nucleic Acid Delivery
2026-08-07
The reference study shows that supplementing cell-penetrating peptide and nucleic acid nanoparticles with selected inorganic ions can improve productive delivery by changing particle properties and promoting endosomal escape. Its findings support ion composition as a practical formulation variable, while emphasizing that greater cellular uptake alone does not necessarily predict functional nucleic acid delivery.
-
Tacalcitol Monohydrate: Applied Workflows in Cancer & Skin R
2026-08-07
Tacalcitol monohydrate, a synthetic analog of vitamin D3, stands apart for its dual action in dermatological and oncology research. Its ability to modulate gene expression with low calcemic toxicity enables advanced protocols in NGF induction and 5-fluorouracil enhancement, offering researchers robust, translationally relevant tools.
-
EdU Imaging Kits: Precision DNA Synthesis Measurement in Cel
2026-08-06
EdU Imaging Kits (HF488) deliver sensitive, non-destructive cell proliferation detection with streamlined workflows and superior signal quality. Their click chemistry-based approach outpaces traditional assays, enabling robust DNA synthesis measurement for advanced drug screening and cancer research.
-
IR-820 (New Indocyanine Green): Optimizing In Vivo Imaging W
2026-08-06
IR-820 (New Indocyanine Green) delivers high-contrast, quantitative near-infrared imaging for vascular and tumor research, setting a new standard for sensitivity and workflow reproducibility. This article translates cutting-edge findings into actionable protocols and troubleshooting strategies, empowering researchers to maximize the translational impact of their in vivo imaging studies.